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CNS  central nervous system 
MS  multiple sclerosis 
RR  relapsing-remitting 
SP  secondary progressive 
PP  primary progressive 
EDSS  Expanded Disability Status Scale 
EAE  experimental autoimmune encephalomyelitis 
MAG  myelin associated glycoprotein 
MG  myasthenia gravis 
MC  myasthenic crisis 
AchR  acetylcholine-receptor 
AchR Abs acetylcholine receptor antibodies 
MusK R Muscle specific Kinase Receptor 
MusK Abs MusK Receptor antibodies 
Anti-Ti Abs titin antibodies 
AZA  azathioprin 
PR  methylprednisolone or prednisolone 
GA  glatiramer acetate 
INFB-1b interferone beta 1-b 
INFB-1a interferone beta 1-a 
LHON  Leber’s hereditary optic neuropathy 
Mt-DNS mitochondrial DNA 
CoQ  coenzyme Q 
NADH  reduced nicotinamide adenine dinucleotide 
GSH  reduced glutathione 
CTLA4 cytotoxic T-lymphocyte-associated antigen-4 
3’UTR  3’ untranslated region 





Neuroimmunology covers diseases of central and peripheral nervous system 
with immunological involvement. Most of the neuroimmunological diseases are of 
autoimmune origin. Such diseases can be classified according to their pathogenesis, 
they can be primary diseases of the nervous system or systemic diseases with 
nervous system involvement. On the other hand, immune-mediated processes can 
affect different neurological structures: the central nervous system, the peripheral 
nerves or the neuromuscular junction.  
The exact definition of the syndromes plays an important role in the selection 
of the exact therapy: since diseases with similar symptoms can be of different 
pathophysiological origin therefore the potentially effective treatments can be distinct. 
The studies that underlie these theses were conducted in three directions: we 
observed and analysed the effects of well known therapies and the effects of 
cessation of some therapies; we studied the background factors and molecular 
markers which have a potential effect on the efficacy of these therapies; and we also 









1. To analyze the safety and tolerability profile of the combined 
immunosuppressive treatment in myasthenia gravis (MG) by long-term 
observation of a great number of patients and with detailed evaluation of 
adverse events. 
2. To evaluate the effect of the combined immunosuppressive treatment on the 
recurrence of myasthenic crisis. 
3. To analyze the negative impacts of the cessation of immunomodulatory 
treatment on multiple sclerosis. 
4. To study the epidemiology of familial MS in Hungary. 
5. To examine differential diagnostic issues in MS and Leber’s hereditary optic 
neuropathy (LHON); analysis of the coexistence of the two diseases and 
investigation of biochemical processes in LHON. 
6. Analysis of molecular markers, their importance in diagnosis, differential 
diagnosis and therapy of neuroimmunological diseases: antibody spectrum in 
myasthenia gravis, genetic associations of autoimmune diseases; 






1. SAFETY OF LONG-TERM COMBINED IMMUNOSUPPRESSIVE TREATMENT 
IN MYASTHENIA GRAVIS. 
163 patients with generalised myasthenia gravis were followed for three years 
in average, who were treated with combined azathioprine-methylprednisolone (PRE-
AZA) medication in the Jahn Ferenc Hospital between 1996-2002. The diagnosis of 
MG was based on typical clinical symptoms, associated with positive EMG and with 
or without seropositivity of antibodies to acetylcholine receptors (AchR). 84,6% of our 
patients were seropositive, 15,4% were seronegative (MuSK antibodies were not 
examined). Immunosuppressive treatment was introduced only to patients with 
generalized MG, who were poor responders to the high dose cholinesterase inhibitor 
monotherapy or suffered previous myasthenic crisis. The patients were classified 
according to the Myasthenia Gravis Foundation of America (MGFA) Classification. 
After the observation period, we divided the patients in two groups: patients in the 
first group didn’t experience adverse effects (AEs) in contrast to patients with AEs in 
the other group. The second group was further divided to “AZA AEs”, “steroid AEs” 
and “AZA+ steroid AEs”. 
The patients visited our out-patient department every 3 months for clinical and 
laboratory assessment. They filled a detailed questionnaire regarding the potential 
AEs of the treatment. We asked specifically for the usual AEs of both drugs and 
inquired the patients if they had experienced any new signs or symptoms during the 
treatment course. Laboratory tests (complete blood count and differential, platelet 
count, liver enzymes, urinalysis, serum glucose, ionogram, urea and creatin) were 
carried out every 2 weeks for the first 3 months of the treatment, every 4 weeks for 
the first year of treatment, and every second month afterwards.  
 Discussion: 
In our prospective, open, observational long-term study of 163 patients the AE 
profile and safety of the combined AZA+ PRE therapy was analysed. The overall 
proportion of AEs in our study was high (61.4%), however most of the AEs could be 
attributed to steroids and were reversible following the discontinuation of the steroid 
treatment, which was possible in 76.7% of the patients after 12-18 months. The 
overall proportion of AEs due to AZA treatment was 20%. Serious AEs resulting in 
treatment discontinuation were observed in only 10 patients. Hematological 
alterations were the most frequently observed AEs of the AZÁA treatment: 
leukopenia, anemia, pancytopenia as well as hepatotoxicity were observed. AZA AEs 
were not dose-dependent, there was no significant difference in the dose of AZA 
between the group of patients with and without AEs. We emphasize that in contrast 
to previous reports, we found a substantially lower proportion of severe infections 
(1.8%). The latency of the AZA-related AE development was variable, but tended to 
be longer in patients with hematologic AEs. The frequency of malignant tumors was 
not higher than expected in an age-matched population. Probability of developing 
AEs correlated with the severity of MG at the beginning of the treatment. The 
proportion of patients, who began the treatment immediately after a myasthenic crisis 
or who were in a severe class IV, had significantly higher risk of developing AEs.  
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2. LONG-TERM EFFECTS OF COMBINED IMMUNOSUPPRESSIVE TREATMENT 
ON MYASTHENIC CRISIS 
Sixty-nine patients with consecutive episodes of MC between 1990-1996 and 
1997-2004 were treated and followed prospectively in our study.  In the first period, 
between 1990-1996, patients were not regularly treated with immunosuppressants on 
long term in Hungary. We could identify 27 patients without immunosuppressive 
treatment with long-term observational data (in average 80 months) during this 
period. They comprise the untreated (non-IM) historical control group. From 1997 all 
patients, who suffered a MC were uniformly treated on long-term with PR-AZA and 
were prospectively followed. We had 42 such patients: they were followed for 64 
months (at least 6 months) in average. Patients with shorter follow-up or patients who 
died during the MC were not eligible for the study. 
There were no significant differences between the study groups regarding the 
basic demographic and clinical data. The clinical symptoms and characteristics of the 
baseline crisis were also similar in the two groups. Next, we analysed the effect of 
combined PR-AZA treatment on the recurrence of MCs. Recurrent crisis occurred in 
59.3% in the non-treated and 19% in the treated group (p<0.001). Since a delayed 
effect of PR-AZA has been suggested, we also examined the number of crisis 
throughout the first 6 months and beyond, up to a maximum of 126 months. Indeed, 
a reduced frequency of recidive crises beyond half a year (p<0.001) explained the 
observed statistical difference, as the number of repeated crises within 6 months 
after the baseline crisis did not differ between the two groups. There were 
significantly fewer admissions to the ICU in the treated group during the follow-up 
period, compared to the untreated group, and the number of occasions of mechanical 
ventilation was also lower. However, we did not find any significant difference in the 
length of mean ICU stay and duration of mechanical ventilation per crisis between the 
two groups. The number of plasma exchanges during the crisis and the dose of 
pyridostigmine were also similar in the two groups. There was no difference in the 
functional outcome one month after the onset of baseline MC, either.  
Discussion: 
Our results suggest that combined PR-AZA treatment does not prevent the 
recidive crises before 6 months after the first crisis. In contrast, or data indicate a 
highly significant decrease in the frequency of recidive MCs beyond 6 months: the 
risk of a recidive crisis was much lower in the treated group. This treatment has no 
effect on the MC itself as it did not influence the duration of the crisis, nor the 
functional outcome after one month.  
 
 
3. EFFECTS OF INTERRUPTED IMMUNOMODULANT THERAPY ON THE 
NEUROLOGICAL STATE OF MULTIPLE SCLEROSIS PATIENTS 
Between 1999 and 2001, there was a special situation in Hungary. The 
patients who had received GA therapy from 1996, were forced to stop treatment in 
1999 and were able to resume it only from 2001. During this 16-month period these 
patients were regularly examined and prospectively followed. In contrast, patients on 
INFB-1b could continue treatment without cessation. Due to this special situation we 
were able to analyze the effect of halting treatment on the course of the disease. 
Six MS centres in Hungary including the Jahn Ferenc Hospital MS centre 
participated in this multicentric study. All patients had relapsing-remitting MS and the 
demographic data of the two study groups were homogenous. The EDSS score, 
which indicates the grade of disability (scores 1-10), was obtained during a 
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neurological examination every three months, or more often if the symptoms 
suggested exacerbation. In consequence of the continuous GA therapy from 1996 to 
1999, the annual relapse rate decreased significantly as compared with the 2-year 
period prior to the immunomodulatory treatment. The annual exacerbation rates in 
the 2-year period prior to the beginning of the study did not differ between the patient 
groups treated with GA and INFB-1b. However, we found a significant increase in the 
annual exacerbation rate relative to the treatment period after the 16-month therapy-
free period. In addition, the annual relapse rate was significantly higher in patients, 
who were forced to stop GA compared to patients treated continuously with INFB-1b. 
EDSS scores were not different. 
Discussion: 
Due to the interrupted therapy, negative trends in the disease course could be 
already seen after 16 months. The annual relapse-rate increased significantly 
compared to the course while on treatment and also to the continuously treated 
INFB-1b treated group. 
 
 
4. EPIDEMIOLOGY OF FAMILIAL MULTIPLE SCLEROSIS IN HUNGARY 
The prevalence of familial MS is between 5-10% in high-risk areas. By 
analyzing data of 1500 patients in five MS centres, familial aggregation of MS in 
Hungary was examined. The patients were diagnosed according to the McDonald’s 
criteria and had relapsing-remitting (RR), secondary progressive (SP) or benign MS. 
We found aggregation of MS in 15 families involving 33 patients, including a 
monozygotic twin pair. The male/female ratio was 1:2.75 similar to sporadic MS in 
Hungary. One patient of the concordant monozygotic twin pair suffered of SPMS 
(EDSS score of 8), while the other had a benign form of the disease. We also found a 
dizygotic twin pair, whose father had died of MS 20 years previously. In another 
family, three generations were affected (mother, son and granddaughter). 
Discussion: 
In our cohort represening 25% of all MS patients in Hungary, we found a 2% 
familial rate. The significant difference in the phenotype of the monozygotic twin pair 
underlines the importance of environmental factors. 
 
 
5. LEBER’S HEREDITARY OPTIC NEUROPATHY (LHON) AND MULTIPLE 
SCLEROSIS 
 
5.1. LHON presenting as multiple sclerosis-like disease of the CNS 
DNA were isolated from 72 patients with bilateral optic neuropathy and tested 
for the three pathogenic mtDNA LHON point mutations.  Pathogenic LHON mutations 
were found in 12 patients. In addition, 27 maternal relatives were examined. As 
expected, all maternal relatives were homoplasmic for the LHON mutation found in 
the related patients. All 39 genetically defined carriers were examined neurologically 
to determine the frequency of MS-like diseases. Two LHON patients (women) 
presented multifocal neurological symptoms. One was homoplasmic for the G11778A 
and the other for the T14484C mutation.  
Discussion: 
We examined 39 patients with genetically defined LHON mutations, 12 
patients with LHON and 27 symptom free carriers, to determine the frequency of 
multicentral neurologic manifestations, especially MS like symptoms. We found two 
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patients with MS-like diseases. In both cases, the CNS involvement was also 
indicated by brain MRI. 
 
5.2. Investigation of the biochemical background of LHON 
The primary atiological event in LHON is a mutation in the mtDNA affecting in 
most cases mtDNA-encoded subunits of the respiratory chain. Complex I is 
embedded in the mitochondrial inner membrane mediating electron transport and 
oxidative phosphorylation. It catalyzes electron transport from NADH to coenzyme Q. 
All three pathogenic LHON mutations involve complex I subunits, therefore it is 
assumed that they affect some functional properties of this enzyme complex. 
However, the relation between complex I dysfunction and disease pathogenesis is 
unclear. The various mtDNA mutants are associated with up to 60% reductions in the 
catalytic activity of complex I in different tissues in patients with LHON. The impaired 
complex I activity leads to a decline in mitochondrial energy production, enhances the 
generation of free radicals and initiates lipid peroxidation. The cells have their 
endogenous defence systems to neutralise reactive oxygen species or the damage 
elicited by these toxic species. The main hydrophilic scavenger found in cytosolic, 
mitochondrial, and nuclear compartments is reduced glutathione (GSH), whereas its 
hydrophobic equivalent localised in membranes is α-tocopherol. Both GSH and α-
tocopherol are potent inhibitors of lipid peroxidation; GSH prevents the initiation of 
radical formation, α-tocopherol inhibits the propagation of the chain reaction. Due to 
these theoretical considerations, we wanted to determine whether patients with 
LHON, and carriers, display any alterations in these main antioxidant systems 
pointing to enhanced free radical reactions. The concentration of GSH, α-tocopherol, 
and some other antioxidants were determined in the blood samples from nine 
patients, seven carrier maternal relatives and 15 control subjects  All of the patients 
with LHON and the carriers had the homoplasmic 11778 point mutation in the 
mtDNA. The α-tocopherol/lipid ratio was significantly reduced (p<0.05) in patients 
with LHON and carriers compared with control subjects. 
Discussion: 
The marked reduction in the plasma α-tocopherol/lipid ratio most probably 
reflects the high consumption of the scavenger molecule by affected tissues. Our 
data suggest that the primary antioxidant against free radicals elicited by complex I 
impairment is α-tocopherol. 
 
 
6. MOLECULAR MARKERS IN MYASTHENIA GRAVIS AND MULTIPLE 
SCLEROSIS 
 
6.1. Multiple sclerosis and myasthenia gravis tissue- and gene bank 
With collaboration of Department of Neurology of University of Pécs and 
Department of Neurology of the Jahn Ferenc Hospital we established a multiple 
sclerosis tissue bank. This bank includes clinical data, genomic DNA and CSF 
samples. Data and samples from 282 patients have been collected so far. 
The HLA-DRB1*1501 genotype was examined altogether in 244 patients. 
Fourty percentage (96 patients) of the Hungarian MS population carries this single 
consistent susceptibility allele of the Caucasian MS.  
The myasthenia gravis databank comprises clinical data, DNA and serum 
samples of 186 myasthenic patients. 
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6.2. Serological subgroups in the Hungarian myasthenia gravis patient 
population 
In collaboration with foreign institutes we examined the distribution of anti-
AchR-, anti-Titin- and anti-MuSK antibodies in 100 patients with myasthenia gravis. 
Summary of results and Discussion: 
We detected AchR Abs in 72 patients i.e. 72% of our patients were 
“seropositive”. Sixteen patients had Abs against the muscle Titin protein. It is 
established that MuSK Abs are present only in seronegative myasthenic patients. 
Therefore we tested the MuSK Abs only in AchR Ab negative and in patients with 
unknown AchR Ab status. We had 40 such patients. Twenty-nine of them turned out 
to be AchR Ab negative, and 4 of them were anti-MuSK positive. 
We examined the combination of various antibodies. We checked weather the 
AchR Ab positive patients have Abs against Titin and MuSK. In 20%, of patients with 
AchR Abs in the sera, Abs against the muscle Titin protein were also present but 
anti-MuSK Abs were not found. When analysing the AchR Ab negative patients, only 
one out of the 29 anti-Titin Ab-positive belonged to this group, but 4 of them were 
anti-MuSK positive. We concluded that Titin Abs are present mostly in patients who 
are AchR Ab positive while MuSK Abs are present exclusively in AchR Ab negative 
patients. We also examined the frequency of AchR Abs in anti-Titin positive and anti-
MuSK positive patients. Sera of 15 out of the 16 anti-Titin positive patients also 
contained anti-AchR Abs, but none of them had MuSK Abs. MuSK Abs were not 
associated with other antibodies. 
In summary, the anti-Titin Abs are usually present together with anti-AchR 
antibodies while anti-MuSK Abs are present alone. Anti-AchR Abs are associated 
with anti-Titin ABs in one third of the patients. AchR Abs and MuSK Abs do not 
appear together. 
 
6.3. Multiple sclerosis and the CTLA4 autoimmunity polymorphism CT60 in 
German, Hungarian, and Polish patients 
One possible candidate for shared autoimmunity genes is the CTLA4 gene, 
the gene of one of the most important T-cell costimulatory factor, the cytoxic T-
lymphocyte-associated antigen-4 (CTLA-4). The CT60 polymorphism in the 3’UTR 
region is associated with several autoimmune diseases. Data about association with 
MS are conflicting. Therefore, we decided to examine the potential association of 
CT60 and one other CTLA4 polymorphysm (+49A/G) in a great number of German, 
Polish and Hungarian MS patients. The three populations were of similar genotypes 
and allele frequencies. The meta-analysis showed no association of MS with CT60 or 
+49A/G allele frequencies. The CT60*G/G genotype was overrepresented among 
MS patients in all three populations, however this finding did not reach statistical 
significance.  
Discussion: 
We could not demonstrate association with MS susceptibility, with age of 
onset, progression and disease course in these patients. The CT60*G/G genotype 
was slightly overrepresented in all three populations. The frequency of +49A/G*g-
CT60*G haplotype was also slightly higher in German, but not Hungarian or Polish 
MS patients. No difference reached statistical significance, and these polymorphism 
does not cause functional changes in CTLA-4 and ICOS expression. In summary, it 
was not possible to demonstrate an association of this common autoimmune 
polymorphism with multiple sclerosis in these large cohort of MS.  
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6.4. 3’UTR C2370A allele of the IL-23 receptor gene is associated with 
relapsing-remitting multiple sclerosis 
Cytokines play an important role in the development of autoimmune diseases. 
IL-23 and IL-17 have recently been suggested to play an important role in the 
pathogenesis of autoimmune diseases such as MS. One of the Th17 differentiation 
pathways is IL-23-dependent and IL-23 is necessary for the survival and expansion 
of IL-17 producing autoimmune Th17 cells.  
Several polymorphisms recently identified in the IL23R gene are associated 
with inflammatory bowel disease (IBD). The C2370A allele in the 3’UTR showed one 
of the most significant associations with IBD. Here, we examined the association of 
this SNP with MS. Patients with RRMS (n=223) were involved in the study, 45 
patients have progressed into a secondary progressive phase following a relapsing-
remitting course. The control population consisted of 200 clinically healthy subjects.  
The AA genotype was significantly over-represented in the 223 MS patients 
compared to 200 healthy controls (10.8% vs 5.5%, p<0.05). The AA genotype was 
also significantly over-represented among patients exhibiting OCB in the CSF. 
Multiple regression analysis revealed that presence of the AA genotype provides a 
two-fold risk for the development of MS and for the presence of oligoclonal bands in 
the CSF. No such differences were observed when HLA-DR15-positive (n=84) or 
negative (n=132) subgroups were separated and compared to healthy subjects. Nor 
did we find any significant differences when female patients were separately 
analyzed, and no association was found with secondary progressive disease course.  
Discussion: 
Our data indicate that a genetic association exists between relapsing-remitting 
MS and the C2370A polymorphism of the IL23R gene. The AA genotype provides a 
two-fold risk for developing MS and oligoclonal bands in the CSF. The susceptibility 
was independent from HLA-DR15 status. Since association of the A2370A genotype 
with other autoimmune diseases was also described, our data also suggest that the 
IL23R may represent a novel common autoimmunity gene. 
 
6.5 Aberrant transcriptional regulatory network in T cells of multiple sclerosis 
Concordance rate in MS for monozygotic (MZ) twins is 25-30%, while it is 2-
5% for dizygotic (DZ) twins suggesting the possible involvement of not a single but 
multiple susceptibility genes in development of MS. Regulation of multiple 
susceptibility genes is controlled through the combinatorial action of multiple 
signalling and multiple transcription factors that form molecular network of genes. We 
performed microarray analysis of peripheral blood T cells isolated from the 
genetically homogeneous population of Hungarian monozygotic concordant and 
discordant MS twins. Molecular network of the differentially expressed genes was 
than analyzed by a comprehensive information platform.  
In 3 of the 4 monozygotic twin-pairs both siblings were ill (concordant twins), in 
one case we had discordant twins with one MS patient and one healthy subject. All 
subjects were females, 33±5 years old and the mean disease duration of 6±5 years. 
All patients exhibited a typical RR disease course, except for one patient who had 
CIS. The patients showed a relatively mild EDSS score of 1.3±0.8. By microarray 
analysis, we identified 50-100 differentially expressed genes (DEG) in T cells 
between each MS twin pair. Then, we compared the genes of the discordant and 
concordant twins, and selected a panel of 34 genes that were listed in 50 
differentially expressed genes of the discordant twin (MR/healthy subject) but were 
not included in 100 DEG of the concordant (MS/MS) twin pairs. In that way we 
 22
investigated in the genetically homogeneous population the gene expression typical 
for MS. We further extracted a set of 20 DEG by a cut-off point greater or equal to 
two-fold difference between the discordant pair. Further 43 genes were identified, 
that are directly linked to 20 DEG, with the computer-analysis. The search of 43 
genes illustrated a complex molecular network composed of 39 nodes. By statistical 
analysis, the generated network showed the most significant relationship with gene 
regulation by the Ets transcription factor family, the gene regulation by the nuclear 
factor NF-κB, the Myc/Mad family, the IFN-regulatory factor (IRF), and the estrogen 
receptor (ER) family.  
Discussion: 
Our data propose the logical hypothesis that aberrant regulation of the 
complex transcriptional regulatory network might contribute to development of 
pathogenic T cells in MS. The Ets family transcription factor controls the expression 
of a wide range of target genes essential for cell proliferation, differentiation, 
transformation, and apoptosis. The NF-κB family acts as a central regulator of innate 
and adaptive immune responses, cell proliferation and apoptosis. It has more than 
150 target genes, and is overexpressed in macrophages and oligodendrocytes of MS 
plaques. The IRF (interferone regulatory factors) together with NF-κB is part of the 
IFN-B gene enhancome, an important regulatory factor of the immune response, cell 






1. The long-term combined (PRE-AZA) therapy in moderately severe and severe 
generalized myasthenia gravis (MGFA Class III-V) is well tolerated, safe and 
effective treatment. The long-term treatment with AZA has a steroid sparing 
effect: steroid treatment could be discontinued in the majority of our cases. 
The adverse effects were due to steroid treatment in most of the patients. 
2. We examined and proved for the first time that the number of recidive crises 
decreases in patients treated with PRE-AZA on long-term. This observation 
supports the necessity of long-term immunosuppressive treatment (PRE-AZA) 
after a myasthenic crisis.  
3. LHON can be differential-diagnostic issue in MS, and can occur with MS or 
MS-like syndromes. 
4. The decrease in disease activity and halt of progression in MS can be 
achieved only with long-term, continuous disease modifying treatment. We 
proved that after the discontinuation of treatment results in an increase of 
relapses. 
5. Our study is the first epidemiological study of Hungarian familial MS cases. 
According to our data the prevalence of familial MS is about 2%.  
6. The twin and association studies are of great importance in the genetic 
research of autoimmune neuroimmunological diseases. To address this issue 
we established DNA and tissue banks in MS and MG. 
7. We studied for first time the frequency of the HLA-DRB1*1501 genotype in the 
Hungarian MS population.  
8. We showed that the CTLA4 CT60 SNP is not associated with MS, while the 
3’UTR C2370A allele of the IL-23 receptor gene doubles the risk of RRMS and 
of OGP in the CSF.  
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